Research Topics
| Steven C DerrickSummaryAffiliation: Food and Drug Administration Country: USA Publications
| Collaborators
|
Detail Information
Publications
Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosisVasan K Sambandamurthy
Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
Infect Immun 73:1196-203. 2005....
The ESAT6 protein of Mycobacterium tuberculosis induces apoptosis of macrophages by activating caspase expressionSteven C Derrick
Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, USA
Cell Microbiol 9:1547-55. 2007..Finally, experimental results using a cell impermeable fluorescent stain suggests that the formation of membrane pores may be a primary mechanism by which ESAT6 evokes an apoptotic response...
Vaccination with a Sindbis virus-based DNA vaccine expressing antigen 85B induces protective immunity against Mycobacterium tuberculosisSteven C Derrick
Laboratory of Mycobacterial Diseases and Cellular Immunology, Building 29 Room 511, CBER FDA, 29 Lincoln Dr, Bethesda, MD 20892, USA
Infect Immun 73:7727-35. 2005..These data show that immunization with Sin85B offers protection similar to BCG in a murine model of pulmonary tuberculosis and suggest that Sin85B-induced protection is dependent upon both innate and acquired immune mechanisms...
Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvantKristopher Kolibab
Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, U S Food and Drug Administration, Bethesda, MD 20892, USA
Clin Vaccine Immunol 17:793-801. 2010....
The safety of post-exposure vaccination of mice infected with Mycobacterium tuberculosisSteven C Derrick
Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, USA
Vaccine 26:6092-8. 2008....
Protection against an aerogenic Mycobacterium tuberculosis infection in BCG-immunized and DNA-vaccinated mice is associated with early type I cytokine responsesCarol Goter-Robinson
Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Building 29/Room 509, CBER/FDA, 29 Lincoln Dr, Bethesda, MD 20892, USA
Vaccine 24:3522-9. 2006..Taken together, these data suggest that the post-infection induction of early type 1 cytokine responses correlate with the induction of long-term protective immunity in vaccinated mice...
Early pulmonary cytokine and chemokine responses in mice immunized with three different vaccines against Mycobacterium tuberculosis determined by PCR arrayJaehyun Lim
Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland 20892, USA
Clin Vaccine Immunol 16:122-6. 2009....
A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunitySteven C Derrick
Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Building 29, Room 502, CBER/FDA, 29 Lincoln Drive, Bethesda, MD 20892, USA
Vaccine 23:780-8. 2004....
Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cellsSteven C Derrick
Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, United States
Vaccine 29:2902-9. 2011..These data support efforts to use MFT cell analyses as a measure of TB vaccine immunogenicity in human immunization studies...
Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosisSteven C Derrick
Laboratory of Mycobacterial Diseases and Cellular Immunology. Division of Veterinary Services, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Bethesda, Maryland 20892, USA
Infect Immun 72:1685-92. 2004..The substantial CD8-mediated protective immunity that was generated in the absence of CD4 cells suggests that it may be possible to develop effective TB vaccines for use in HIV-infected populations...
Characterization of the protective T-cell response generated in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis vaccineSteven C Derrick
Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
Immunology 120:192-206. 2007....
Mycobacterium bovis BCG immunization induces protective immunity against nine different Mycobacterium tuberculosis strains in miceBo Young Jeon
Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland 20892, USA
Infect Immun 76:5173-80. 2008..tuberculosis strains in the mouse model of pulmonary tuberculosis and suggest that strain-specific resistance to BCG-induced protective immunity may be uncommon...
Characterization of an intracellular ATP assay for evaluating the viability of live attenuated mycobacterial vaccine preparationsKristopher Kolibab
Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD 20892, USA
J Microbiol Methods 90:245-9. 2012..Overall, these data indicate that the ATP luminescence assay is a rapid, sensitive, and reliable alternative method for quantifying the viability of varying live attenuated mycobacterial vaccine preparations...
A practical in vitro growth inhibition assay for the evaluation of TB vaccinesKristopher Kolibab
Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, United States
Vaccine 28:317-22. 2009..Overall, we have shown that a BSL-2 compatible in vitro growth inhibition assay using INH(r) BCG as the intra-macrophage target organism should be useful in developing and evaluating new TB immunization strategies...
Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosisJoseph Hinchey
Department of Microbiology and Immunology and Howard Hughes Medical Institute, Albert Einstein College of Medicine, New York, New York 10461, USA
J Clin Invest 117:2279-88. 2007..bovis bacille Calmette-Guérin vaccination. Our results define a mechanism for a key immune evasion strategy of M. tuberculosis and provide what we believe to be a novel approach for improving mycobacterial vaccines...
Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosisVasan K Sambandamurthy
Department of Microbiology and Immunology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, United States
Vaccine 24:6309-20. 2006..tuberculosis. Given its overall safety and effectiveness, the mc(2)6030 live attenuated strain should be considered as a human vaccine candidate for protecting both healthy and HIV-infected individuals against TB...
The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissueTsungda Hsu
Howard Hughes Medical Institute, Department of Pathology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Proc Natl Acad Sci U S A 100:12420-5. 2003..We conclude that the primary attenuating mechanism of bacillus Calmette-Guérin is the loss of cytolytic activity mediated by secreted ESAT-6, which results in reduced tissue invasiveness...
